JOHNSON & JOHNSON - FORM 8-K - EX-99.2 - July 16, 2020

Attached files

file filename
EX-99.1 - EX-99.1 - JOHNSON & JOHNSONa2020q2exhibit991.htm
8-K - 8-K - JOHNSON & JOHNSONjnj-20200716.htm

Exhibit 99.2


Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)SECOND QUARTER
Percent Change
20202019TotalOperationsCurrency
Sales to customers by
geographic area
U.S.$ 9,53910,403(8.3)%(8.3)-
Europe4,0634,733(14.2)(11.5)(2.7)
Western Hemisphere excluding U.S.1,1331,455(22.1)(8.9)(13.2)
Asia-Pacific, Africa3,6013,971(9.3)(7.7)(1.6)
International8,79710,159(13.4)(9.6)(3.8)
Worldwide$ 18,33620,562(10.8)%(9.0)(1.8)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.




Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)SIX MONTHS
Percent Change
20202019TotalOperationsCurrency
Sales to customers by
geographic area
U.S.$ 20,23820,532(1.4)%(1.4)-
Europe8,8909,342(4.8)(2.1)(2.7)
Western Hemisphere excluding U.S.2,6352,958(10.9)(0.1)(10.8)
Asia-Pacific, Africa7,2647,751(6.3)(4.9)(1.4)
International18,78920,051(6.3)(2.9)(3.4)
Worldwide$ 39,02740,583(3.8)%(2.2)(1.6)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.







Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)SECOND QUARTER
 Percent Change
20202019TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health
    U.S.$1,557  1,537  1.3  %1.3—  
    International1,739  2,007  (13.4) (7.4) (6.0) 
3,296     3,544  (7.0) (3.6) (3.4) 
Pharmaceutical
    U.S.6,120  5,783  5.8  5.8—  
    International4,632  4,746  (2.4) 1.4(3.8) 
10,752     10,529  2.1  3.9(1.8) 
Medical Devices
    U.S.1,862     3,083  (39.6) (39.6) —  
    International2,426  3,406  (28.8) (26.4) (2.4) 
 4,288     6,489  (33.9) (32.7) (1.2) 
U.S.9,539  10,403  (8.3) (8.3) —  
International8,797  10,159  (13.4) (9.6) (3.8) 
Worldwide$18,336  20,562  (10.8) %(9.0) (1.8) 
   
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.






Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)SIX MONTHS
Percent Change
20202019TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health
U.S.$3,297  2,97510.8%10.8-
International3,6243,887(6.8)(1.9)(4.9)
6,9216,8620.93.6(2.7)
Pharmaceutical
U.S.12,18111,3657.27.2-
International9,7059,4083.26.7(3.5)
21,88620,7735.47.0(1.6)
Medical Devices
U.S.4,7606,192(23.1)(23.1)-
International5,4606,756(19.2)(16.8)(2.4)
10,22012,948(21.1)(19.8)(1.3)
U.S.20,23820,532(1.4)(1.4)-
International18,78920,051(6.3)(2.9)(3.4)
Worldwide$39,027  40,583(3.8)%(2.2)(1.6)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.





Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)SECOND QUARTER
20202019Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$18,336  100.0$20,562  100.0(10.8) 
Cost of products sold6,579  35.96,940  33.8(5.2) 
Gross Profit11,757  64.113,622  66.2(13.7) 
Selling, marketing and administrative expenses4,993  27.25,546  27.0(10.0) 
Research and development expense2,707  14.82,666  13.01.5  
In-process research and development6  0.0  —  —  
Interest (income) expense, net26  0.2  (5) 0.0   
Other (income) expense, net24  0.1  (1,683) (8.2)  
Restructuring61  0.357  0.2 
Earnings before provision for taxes on income3,940  21.57,041  34.2(44.0) 
Provision for taxes on income314  1.71,434  6.9(78.1) 
Net earnings$3,626  19.8$5,607  27.3(35.3) 
Net earnings per share (Diluted)$1.36  $2.08  (34.6) 
Average shares outstanding (Diluted)2,665.5  2,691.7  
Effective tax rate8.0  %20.4  %
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$5,337  29.1$8,614  41.9(38.0) 
Net earnings$4,446  24.2$6,950  33.8(36.0) 
Net earnings per share (Diluted)$1.67  $2.58  (35.3) 
Effective tax rate16.7  %19.3  %
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.








Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)SIX MONTHS
20202019Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$39,027  100.0$40,583  100.0(3.8)
Cost of products sold13,64135.013,55533.40.6
Gross Profit25,38665.027,02866.6(6.1)
Selling, marketing and administrative expenses10,19626.110,76526.5(5.3)
Research and development expense5,28713.55,52413.6(4.3)
In-process research and development60.08902.2
Interest (income) expense, net(16)0.0(2)0.0
Other (income) expense, net(655)(1.7)(1,705)(4.2)
Restructuring1190.3930.3
Earnings before provision for taxes on income10,44926.811,46328.2(8.8)
Provision for taxes on income1,0272.72,1075.1(51.3)
Net earnings$9,422  24.1$9,356  23.10.7
Net earnings per share (Diluted)$3.53  $3.47  1.7
Average shares outstanding (Diluted)2,671.02,697.0
Effective tax rate9.8%18.4%
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$12,581  32.2$15,481  38.1(18.7)
Net earnings$10,600  27.2$12,611  31.1(15.9)
Net earnings per share (Diluted)$3.97  $4.68  (15.2)
Effective tax rate15.7%18.5%
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.


Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Second Quarter
(Dollars in Millions Except Per Share Data)20202019
Net Earnings, after-tax as reported$3,626$5,607
Pre-tax Adjustments
Intangible Asset Amortization expense1,1271,118
Litigation expense, net613409
IPR&D6—
Restructuring related115142
Acquisition and Integration related2955
Unrealized (gains)/losses on securities (533)(148)
Medical Device Regulation 1
37—
Other3(3)
Tax Adjustments
Tax impact on special item adjustments 2
(253)(230)
Tax legislation and related impacts (324)—
Adjusted Net Earnings, after-tax$4,446$6,950
Average shares outstanding (Diluted)2,665.52,691.7
Adjusted net earnings per share (Diluted)$1.67$2.58
Operational adjusted net earnings per share (Diluted)$1.69 
Notes:
1 European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance.
2 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.







Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Six Months Ended
(Dollars in Millions Except Per Share Data)20202019
Net Earnings, after-tax as reported$9,422$9,356
Pre-tax Adjustments
Intangible Asset Amortization expense2,2452,248
Litigation expense, net733832
IPR&D6890
Restructuring related233232
Acquisition and Integration related ¹(933)122
Unrealized (gains)/losses on securities(206)(306)
Medical Device Regulation 2
51-
Other3-
Tax Adjustments
Tax impact on special item adjustments 3
(520)(763)
Tax legislation and related impacts(434)-
Adjusted Net Earnings, after-tax$10,600$12,611
Average shares outstanding (Diluted)2,671.02,697.0
Adjusted net earnings per share (Diluted)$3.97$4.68
Operational adjusted net earnings per share (Diluted)$4.01
Notes:
1 Acquisition and integration related costs for the six months of 2020 primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition.
2 European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance.
3 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.




Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
 SECOND QUARTER 2020 ACTUAL vs. 2019 ACTUAL
 Segments
Consumer Health Pharmaceutical  Medical Devices  Total
 WW As Reported (7.0)%2.1 %(33.9)%(10.8)%
 U.S. 1.3 %5.8 %(39.6)%(8.3)%
 International (13.4)%(2.4)%(28.8)%(13.4)%
 WW Currency (3.4)(1.8)(1.2)(1.8)
 U.S. ————
 International (6.0)(3.8)(2.4)(3.8)
 WW Operational (3.6)%3.9 %(32.7)%(9.0)%
 U.S. 1.3 %5.8 %(39.6)%(8.3)%
 International (7.4)%1.4 %(26.4)%(9.6)%
General Surgery
Advanced Sterilization Products0.10.1
 U.S. 0.00.0
 International 0.30.2
Baby Care
Baby Center0.30.0
 U.S. 0.70.1
 International 0.00.0
All Other Acquisitions and Divestitures0.00.00.10.1
 U.S. 0.00.00.10.0
 International (0.1)0.10.00.0
WW Adjusted Operational(3.4)%3.9 %(32.5)%(8.8)%
 U.S. 2.0 %5.8 %(39.5)%(8.1)%
 International (7.5)%1.5 %(26.1)%(9.4)%
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.








Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
SIX MONTHS 2020 ACTUAL vs. 2019 ACTUAL
Segments
Consumer HealthPharmaceuticalMedical DevicesTotal
WW As Reported0.9 %5.4 %(21.1)%(3.8)%
U.S.10.8 %7.2 %(23.1)%(1.4)%
International(6.8)%3.2 %(19.2)%(6.3)%
WW Currency(2.7)(1.6)(1.3)(1.6)
U.S.————
International(4.9)(3.5)(2.4)(3.4)
WW Operational3.6 %7.0 %(19.8)%(2.2)%
U.S.10.8 %7.2 %(23.1)%(1.4)%
International(1.9)%6.7 %(16.8)%(2.9)%
Skin Health / Beauty
Dr. Ci Labo - Japan(0.2)0.0
U.S.0.00.0
International(0.4)(0.1)
General Surgery
Advanced Sterilization Products1.00.4
U.S.1.10.4
International0.90.4
Baby Care
Baby Center0.30.0
U.S.0.70.1
International0.00.0
All Other Acquisitions and Divestitures(0.1)0.10.00.0
U.S.0.00.10.00.1
International(0.2)0.00.00.0
WW Adjusted Operational3.6 %7.0 %(18.8)%(1.7)%
U.S.11.5 %7.2 %(22.0)%(0.8)%
International(2.5)%6.7 %(15.9)%(2.6)%
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.


Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20202019Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2) (3)
BABY CARE
US$9699(3.5)%(3.5)%— %
Intl260344(24.3) (16.6) (7.7) 
WW356443(19.7) (13.6) (6.1) 
ORAL CARE
US1701559.7  9.7  —  
Intl227234(2.8) 4.0  (6.8) 
WW397  3892.2  6.3  (4.1) 
OTC
US62748429.6  29.6  —  
Intl522580(10.1) (5.0) (5.1) 
WW1,149  1,064  7.9  10.7  (2.8) 
SKIN HEALTH / BEAUTY (4)
US536663(19.2) (19.2) —  
Intl471539(12.5) (8.2) (4.3) 
WW1,007  1,202  (16.2) (14.3) (1.9) 
WOMEN'S HEALTH
US33(2.9) (2.9) —  
Intl199250(20.4) (12.0) (8.4) 
WW202253(20.1) (11.8) (8.3) 
WOUND CARE / OTHER
US126132(4.7) (4.7) —  
Intl5961(2.4) 3.7  (6.1) 
WW185193(4.0) (2.1) (1.9) 
TOTAL CONSUMER HEALTH
US1,557  1,537  1.3  1.3  —  
Intl1,739  2,007  (13.4) (7.4) (6.0) 
WW$3,296  3,544  (7.0)%(3.6)%(3.4)%
See footnotes at end of schedule





Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5)
IMMUNOLOGY
US$2,3622,379(0.7)%(0.7)%— %
Intl1,1611,0876.8  11.0  (4.2) 
WW3,5233,4661.6  3.0  (1.4) 
     REMICADE
     US593801(25.8) (25.8) —  
     US Exports (6)
13362**—  
     Intl208244(14.5) (8.7) (5.8) 
     WW9351,107(15.5) (14.2) (1.3) 
     SIMPONI / SIMPONI ARIA
     US256281(8.7) (8.7) —  
     Intl2892822.6  6.8  (4.2) 
     WW546563(3.0) (0.9) (2.1) 
     STELARA
     US1,1381,0587.5  7.5  —  
     Intl55849911.9  15.5  (3.6) 
     WW1,6971,5588.9  10.1  (1.2) 
     TREMFYA
     US241  176  36.7  36.7  —  
     Intl101  59  71.0  73.4  (2.4) 
     WW342  235  45.4  46.0  (0.6) 
     OTHER IMMUNOLOGY
     US—  —  —  —  —  
     Intl3311.8  21.6  (9.8) 
     WW3311.8  21.6  (9.8) 
INFECTIOUS DISEASES
US4163877.4  7.4  —  
Intl463475(2.5) 2.6  (5.1) 
WW8788621.9  4.7  (2.8) 
     EDURANT / rilpivirine
     US10  12  (14.0) (14.0) —  
     Intl246  198  24.5  27.7  (3.2) 
     WW256  210  22.2  25.2  (3.0) 
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US37934410.5  10.5  —  
     Intl130191(32.0) (26.1) (5.9) 
     WW510535(4.7) (2.6) (2.1) 
     OTHER INFECTIOUS DISEASES
     US2531(18.7) (18.7) —  
     Intl87861.0  8.7  (7.7) 
     WW113117(4.2) 1.5  (5.7) 
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued)
NEUROSCIENCE
US$77866417.4 %17.4 %— %
Intl809875(7.6) (4.1) (3.5) 
WW1,5871,5383.2  5.2  (2.0) 
     CONCERTA / methylphenidate
     US5515**—  
     Intl94123(23.0) (20.2) (2.8) 
     WW1491378.7  11.2  (2.5) 
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US57650613.8  13.8  —  
     Intl303312  (2.8) 0.3  (3.1) 
     WW8798187.5  8.6  (1.1) 
     RISPERDAL CONSTA
     US7481(9.3) (9.3) —  
     Intl79101(21.2) (18.1) (3.1) 
     WW153182(15.9) (14.2) (1.7) 
     OTHER NEUROSCIENCE
     US756221.5  21.5  —  
     Intl331340(2.5) 1.7  (4.2) 
     WW4064011.2  4.7  (3.5) 
ONCOLOGY
US1,1811,01316.6  16.6  —  
Intl1,609  1,684  (4.4) (0.9) (3.5) 
WW2,7912,6973.5  5.7  (2.2) 
     DARZALEX
     US492  369  32.9  32.9  —  
     Intl409  405  1.2  5.9  (4.7) 
     WW901  774  16.3  18.8  (2.5) 
     ERLEADA
     US136  62  **—  
     Intl33  7  ***
     WW170  69  ***
     IMBRUVICA
     US447  367  21.5  21.5  —  
     Intl502  463  8.3  13.4  (5.1) 
     WW949  831  14.1  17.0  (2.9) 
     VELCADE
     US—  —  —  —  —  
     Intl98224(56.1) (55.2) (0.9) 
     WW98224(56.1) (55.2) (0.9) 
     ZYTIGA / abiraterone acetate
     US87198  (55.6) (55.6) —  
     Intl480500(3.9) (2.0) (1.9) 
     WW568698(18.6) (17.2) (1.4) 
     OTHER ONCOLOGY
     US20  16  22.9  22.9  —  
     Intl87852.2  5.9  (3.7) 
     WW1061015.5  8.6  (3.1) 
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued)
PULMONARY HYPERTENSION
US$545  439  24.2 %24.2 %— %
Intl243  251  (3.3) (1.0) (2.3) 
WW789  690  14.2  15.0  (0.8) 
     OPSUMIT
     US256  203  26.1  26.1  —  
     Intl150  146  3.0  5.7  (2.7) 
     WW406  348  16.5  17.6  (1.1) 
     UPTRAVI
     US254  175  44.5  44.5  —  
     Intl28  28  4.0  7.3  (3.3) 
     WW282  203  39.0  39.5  (0.5) 
     OTHER PULMONARY HYPERTENSION
     US37  61  (40.2) (40.2) —  
     Intl64  78  (17.6) (16.4) (1.2) 
     WW101  140  (27.5) (26.9) (0.6) 
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5) Continued)
CARDIOVASCULAR / METABOLISM / OTHER
US$837902(7.2)%(7.2)%— %
Intl347373(7.0) (2.4) (4.6) 
WW1,1841,275(7.1) (5.8) (1.3) 
     XARELTO
     US559  549  1.7  1.7  —  
     Intl—  —  —  —  —  
     WW559  549  1.7  1.7  —  
     INVOKANA / INVOKAMET
     US132  132  (0.8) (0.8) —  
     Intl47  43  9.1  14.8  (5.7) 
     WW179  177  1.6  3.1  (1.5) 
     PROCRIT / EPREX
     US70  113  (38.3) (38.3) —  
     Intl66  70  (5.0) (2.3) (2.7) 
     WW136  183  (25.6) (24.6) (1.0) 
     OTHER
     US78  107  (27.7) (27.7) —  
     Intl234  260  (10.2) (5.3) (4.9) 
     WW312  368  (15.3) (11.8) (3.5) 
TOTAL PHARMACEUTICAL
US6,1205,7835.8  5.8  —  
Intl4,6324,746(2.4) 1.4  (3.8) 
WW$10,75210,5292.1 %3.9 %(1.8)%
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20202019Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (5)
INTERVENTIONAL SOLUTIONS
US$255  366  (30.5)%(30.5)%— %
Intl335  385(12.8) (10.9) (1.9) 
WW590  750(21.5) (20.5) (1.0) 
ORTHOPAEDICS
US869  1,331  (34.7) (34.7) —  
Intl583  894  (34.8) (32.6) (2.2) 
WW1,451  2,224  (34.7) (33.9) (0.8) 
     HIPS
     US137  216  (36.5) (36.5) —  
     Intl88  147  (39.8) (37.3) (2.5) 
     WW226  364  (37.8) (36.8) (1.0) 
     KNEES
     US108  218  (50.5) (50.5) —  
     Intl66  153  (56.8) (55.3) (1.5) 
     WW174  372  (53.1) (52.5) (0.6) 
     TRAUMA
     US354  407  (12.9) (12.9) —  
     Intl198  265  (25.2) (22.6) (2.6) 
     WW553  672  (17.8) (16.7) (1.1) 
     SPINE, SPORTS & OTHER (7)
     US270  490  (45.0) (45.0) —  
     Intl230  328  (29.9) (27.9) (2.0) 
     WW499  818  (39.0) (38.2) (0.8) 
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
SECOND QUARTER
% Change
20202019Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (5) (Continued)
SURGERY
US$490  926  (47.0)%(47.0)%— %
Intl1,060  1,427  (25.7) (22.6) (3.1) 
WW1,551  2,353  (34.1) (32.2) (1.9) 
     ADVANCED
     US277  396  (30.0) (30.0) —  
     Intl498  633  (21.2) (18.4) (2.8) 
     WW775  1,029  (24.6) (22.9) (1.7) 
     GENERAL
     US213  530  (59.8) (59.8) —  
     Intl562  794  (29.2) (26.0) (3.2) 
     WW775  1,325  (41.5) (39.5) (2.0) 
VISION
US248  461  (46.1) (46.1) —  
Intl447  701  (36.1) (34.8) (1.3) 
WW695  1,161  (40.1) (39.3) (0.8) 
     CONTACT LENSES / OTHER
     US203  333  (39.0) (39.0) —  
     Intl352  509  (30.9) (29.6) (1.3) 
     WW554  842  (34.1) (33.3) (0.8) 
     SURGICAL
     US45  128  (64.6) (64.6) —  
     Intl96  191  (49.9) (48.8) (1.1) 
     WW141  319  (55.8) (55.2) (0.6) 
TOTAL MEDICAL DEVICES
US1,862  3,083  (39.6) (39.6) —  
Intl2,426  3,406  (28.8) (26.4) (2.4) 
WW$4,288  6,489  (33.9)%(32.7)%(1.2)%




Johnson & Johnson
Segment Sales
(Dollars in Millions)
SIX MONTHS
% Change
20202019Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2) (3)
BABY CARE
US$188  186  1.2 %1.2 %—%
Intl529  651  (18.7) (12.6) (6.1) 
WW717  837  (14.3) (9.5) (4.8) 
ORAL CARE
US346  306  12.9  12.9  —
Intl446  450  (0.8) 4.6  (5.4) 
WW792  756  4.8  8.0  (3.2) 
OTC
US1,316  991  32.8  32.8  —
Intl1,181  1,160  1.8  6.0  (4.2) 
WW2,497  2,151  16.1  18.3  (2.2) 
SKIN HEALTH / BEAUTY (4)
US1,195  1,251  (4.5) (4.5) —
Intl929  1,041  (10.7) (7.4) (3.3) 
WW2,124  2,292  (7.3) (5.8) (1.5) 
WOMEN'S HEALTH
US7  6  14.3  14.3  —
Intl427  472  (9.6) (2.1) (7.5) 
WW434  478  (9.3) (1.9) (7.4) 
WOUND CARE / OTHER
US245  234  4.7  4.7  —
Intl111  114  (1.9) 2.8  (4.7) 
WW356  348  2.6  4.1  (1.5) 
TOTAL CONSUMER HEALTH
US3,297  2,975  10.8  10.8  —
Intl3,624  3,887  (6.8) (1.9) (4.9) 
WW$6,921  6,862  0.9 %3.6 %(2.7)%
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
SIX MONTHS
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5)
IMMUNOLOGY
US$4,772  4,542  5.1 %5.1 %—%
Intl2,389  2,175  9.8  13.7  (3.9) 
WW7,161  6,717  6.6  7.9  (1.3) 
     REMICADE
     US1,218  1,575  (22.7) (22.7) —
     US Exports (6)
243  138  75.7  75.7  —
     Intl464  496  (6.4) (1.6) (4.8) 
     WW1,925  2,209  (12.9) (11.8) (1.1) 
     SIMPONI / SIMPONI ARIA
     US528  544  (2.9) (2.9) —
     Intl547  543  0.8  4.8  (4.0) 
     WW1,075  1,087  (1.1) 1.0  (2.1) 
     STELARA
     US2,355  1,940  21.4  21.4  —
     Intl1,161  1,022  13.6  16.9  (3.3) 
     WW3,516  2,963  18.7  19.8  (1.1) 
     TREMFYA
     US428  344  24.4  24.4  —
     Intl210  108  94.0  97.1  (3.1) 
     WW638  452  41.1  41.8  (0.7) 
     OTHER IMMUNOLOGY
     US—  —  ———
     Intl6  6  2.7  8.4  (5.7) 
     WW6  6  2.7  8.4  (5.7) 
INFECTIOUS DISEASES
US852  744  14.5  14.5  —
Intl946  964  (1.8) 2.7  (4.5) 
WW1,798  1,708  5.3  7.8  (2.5) 
     EDURANT / rilpivirine
     US22  24  (6.9) (6.9) —
     Intl458  397  15.4  18.4  (3.0) 
     WW480  421  14.1  17.0  (2.9) 
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US775  659  17.7  17.7  —
     Intl314  399  (21.4) (15.8) (5.6) 
     WW1,089  1,058  2.9  5.0  (2.1) 
     OTHER INFECTIOUS DISEASES
     US54  61  (11.2) (11.2) —
     Intl174  168  3.8  9.4  (5.6) 
     WW229  229  (0.2) 3.9  (4.1) 
See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)
SIX MONTHS
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued)
NEUROSCIENCE
US$1,526  1,387  10.1 %10.1 %—%
Intl1,719  1,780  (3.5) (0.5) (3.0) 
WW3,245  3,167  2.5  4.1  (1.6) 
     CONCERTA / methylphenidate
     US107  112  (4.2) (4.2) —
     Intl212  239  (11.0) (8.6) (2.4) 
     WW320  351  (8.9) (7.2) (1.7) 
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US1,120  989  13.2  13.2  —
     Intl642  619  3.7  6.7  (3.0) 
     WW1,762  1,608  9.5  10.7  (1.2) 
     RISPERDAL CONSTA
     US150  158  (4.9) (4.9) —
     Intl173  203  (14.9) (11.9) (3.0) 
     WW323  361  (10.5) (8.9) (1.6) 
     OTHER NEUROSCIENCE
     US150  128  16.8  16.8  —
     Intl691  719  (3.9) (0.8) (3.1) 
     WW841  847  (0.7) 1.8  (2.5) 
ONCOLOGY
US2,356  1,975  19.3  19.3  —
Intl3,448  3,240  6.4  9.9  (3.5) 
WW5,804  5,215  11.3  13.5  (2.2) 
     DARZALEX
     US955  721  32.3  32.3  —
     Intl883  682  29.6  34.7  (5.1) 
     WW1,838  1,403  31.0  33.5  (2.5) 
     ERLEADA
     US255  120  **—
     Intl57  10  ***
     WW313  130  ***
     IMBRUVICA
     US879  716  22.6  22.6  —
     Intl1,101  898  22.6  27.4  (4.8) 
     WW1,980  1,615  22.6  25.3  (2.7) 
     VELCADE
     US—  —  ———
     Intl206  487  (57.7) (56.9) (0.8) 
     WW206  487  (57.7) (56.9) (0.8) 
     ZYTIGA / abiraterone acetate
     US226  383  (40.9) (40.9) —
     Intl1,032  994  3.8  6.1  (2.3) 
     WW1,258  1,377  (8.6) (7.0) (1.6) 
     OTHER ONCOLOGY
     US42  34  21.4  21.4  —
     Intl169  169  (0.3) 3.3  (3.6) 
     WW210  203  3.4  6.3  (2.9) 
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
SIX MONTHS
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued)
PULMONARY HYPERTENSION
US$1,031  869  18.7 %18.7 %—%
Intl503  477  5.3  7.9  (2.6) 
WW1,534  1,346  13.9  14.9  (1.0) 
     OPSUMIT
     US485  375  29.3  29.3  —
     Intl310  279  11.2  14.1  (2.9) 
     WW795  654  21.6  22.8  (1.2) 
     UPTRAVI
     US466  351  32.6  32.6  —
     Intl66  50  33.6  37.6  (4.0) 
     WW532  401  32.7  33.2  (0.5) 
     OTHER PULMONARY HYPERTENSION
     US81  143  (43.5) (43.5) —
     Intl126  149  (15.1) (13.7) (1.4) 
     WW207  292  (29.0) (28.3) (0.7) 
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
SIX MONTHS
% Change
20202019Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (5) (Continued)
CARDIOVASCULAR / METABOLISM / OTHER
US$1,643  1,849  (11.1)%(11.1)%—%
Intl701  771  (9.1) (5.6) (3.5) 
WW2,344  2,620  (10.5) (9.5) (1.0) 
     XARELTO
  
     US1,086  1,091  (0.5) (0.5) —
     Intl—  —  ———
     WW1,086  1,091  (0.5) (0.5) —
     INVOKANA / INVOKAMET
  
     US249  286  (13.0) (13.0) —
     Intl105  92  14.1  18.1  (4.0) 
     WW354  379  (6.4) (5.5) (0.9) 
     PROCRIT / EPREX
  
     US146  261  (44.1) (44.1) —
     Intl145  148  (2.2) (0.1) (2.1) 
     WW291  409  (28.9) (28.2) (0.7) 
     OTHER
  
     US163  211  (22.9) (22.9) —
     Intl451  531  (15.0) (11.3) (3.7) 
     WW614  742  (17.3) (14.6) (2.7) 
TOTAL PHARMACEUTICAL
US12,181  11,365  7.2  7.2  —
Intl9,705  9,408  3.2  6.7  (3.5) 
WW$21,886  20,773  5.4 %7.0 %(1.6)%
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
SIX MONTHS
% Change
20202019Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (5)
INTERVENTIONAL SOLUTIONS
US$620  709  (12.6)%(12.6)%—%
Intl697  774  (9.9) (8.0) (1.9) 
WW1,317  1,482  (11.2) (10.2) (1.0) 
ORTHOPAEDICS
US2,119  2,649  (20.0) (20.0) —
Intl1,371  1,779  (22.9) (20.6) (2.3) 
WW3,489  4,428  (21.2) (20.3) (0.9) 
     HIPS
     US343  429  (20.1) (20.1) —
     Intl220  295  (25.4) (22.8) (2.6) 
     WW563  725  (22.3) (21.2) (1.1) 
     KNEES
     US322  441  (27.1) (27.1) —
     Intl196  299  (34.6) (32.7) (1.9) 
     WW517  741  (30.1) (29.3) (0.8) 
     TRAUMA
     US761  824  (7.6) (7.6) —
     Intl445  533  (16.5) (13.9) (2.6) 
     WW1,207  1,357  (11.1) (10.0) (1.1) 
     SPINE, SPORTS & OTHER (7)
     US693  955  (27.4) (27.4) —
     Intl510  651  (21.7) (19.6) (2.1) 
     WW1,202  1,606  (25.1) (24.3) (0.8) 
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
SIX MONTHS
% Change
20202019Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (5) (Continued)
SURGERY
US$1,334  1,927  (30.8)%(30.8)%—%
Intl2,317  2,821  (17.9) (14.8) (3.1) 
WW3,651  4,748  (23.1) (21.3) (1.8) 
     ADVANCED
     US658  800  (17.7) (17.7) —
     Intl1,065  1,209  (11.9) (8.9) (3.0) 
     WW1,723  2,009  (14.2) (12.4) (1.8) 
     GENERAL
     US676  1,127  (40.0) (40.0) —
     Intl1,252  1,612  (22.4) (19.2) (3.2) 
     WW1,928  2,739  (29.6) (27.8) (1.8) 
VISION
US687  907  (24.2) (24.2) —
Intl1,075  1,383  (22.3) (20.8) (1.5) 
WW1,762  2,290  (23.0) (22.2) (0.8) 
     CONTACT LENSES / OTHER
     US549  654  (16.1) (16.1) —
     Intl819  1,011  (19.0) (17.6) (1.4) 
     WW1,368  1,666  (17.9) (17.0) (0.9) 
     SURGICAL
     US138  253  (45.3) (45.3) —
     Intl256  371  (31.0) (29.6) (1.4) 
     WW394  624  (36.8) (36.0) (0.8) 
TOTAL MEDICAL DEVICES
US4,760  6,192  (23.1) (23.1) —
Intl5,460  6,756  (19.2) (16.8) (2.4) 
WW$10,220  12,948  (21.1)%(19.8)%(1.3)%
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-
rounded figures and, therefore, may not recalculate precisely.
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Previously referred to as Consumer
(4) Previously referred to as Beauty
(5) Certain prior year amounts have been reclassified to conform to current year product disclosures
(6) Reported as U.S. sales
(7) Previously referred to as Spine & Other



Stock widget

Investing forum

JOHNSON & JOHNSON Reports